Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Hims & Hers Health, Inc. related to misleading statements and actions that may have jeopardized shareholder interests [1]. Group 1: Allegations Against Hims & Hers Health, Inc. - Insiders at Hims & Hers Health allegedly misrepresented or failed to disclose involvement in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [1]. - There is a substantial risk that the company's collaboration with Novo Nordisk could be terminated due to these actions [1]. - Positive statements regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis [1].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Sarepta Therapeutics, Inc. related to the misrepresentation of safety risks associated with the ELEVIDYS treatment [1] Group 1: Allegations Against Sarepta Therapeutics - Insiders at Sarepta Therapeutics allegedly caused the company to misrepresent or fail to disclose significant safety risks posed by the ELEVIDYS treatment [1] - The trial regimes and protocols for ELEVIDYS reportedly failed to detect severe side effects, leading to concerns about patient safety [1] - The severity of adverse events from ELEVIDYS treatment may result in the company halting recruitment and dosing in trials, attracting regulatory scrutiny, and increasing risks around the therapy's approvals [1] - Insiders are accused of materially misleading stakeholders and lacking a reasonable basis for their positive statements regarding ELEVIDYS [1]

Core Insights - The Ademi Firm is investigating Semler Scientific for potential breaches of fiduciary duty and other legal violations related to its transaction with Strive [1][3] - Shareholders of Semler Scientific will receive 21.05 Class A common shares of Strive, valued at approximately $90.52 per share based on trading prices as of September 19, 2025 [2] - The transaction agreement restricts competing offers for Semler Scientific by imposing significant penalties for accepting alternative bids, raising concerns about the board's fiduciary responsibilities [3]

Core Points - Metsera (Nasdaq: MTSR) is involved in a transaction with Pfizer, where shareholders will receive $47.50 per share, resulting in an enterprise value of approximately $4.9 billion [2][3] - The transaction agreement includes provisions that significantly limit competing offers for Metsera, imposing penalties if a competing bid is accepted [3] Investigation Details - The Ademi Firm is investigating potential breaches of fiduciary duty by Metsera's board of directors regarding their responsibilities to shareholders in light of the transaction with Pfizer [1][3] - The investigation focuses on whether the board is acting in the best interests of all shareholders, given the substantial benefits insiders will receive from change of control arrangements [2][3]

Core Viewpoint - Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of Tempus AI, Inc. regarding the company's representation as an AI firm despite limited revenue generation from AI solutions [1] Company Overview - Tempus AI primarily generates revenue from acquisitions, genomic testing, and data licensing agreements rather than from AI solutions [1] - The company has emphasized its relationship with AstraZeneca, citing it as a long-term customer and an example of secure and expanding data licensing agreements [1] Recent Developments - Tempus announced an expanding contract with AstraZeneca through a joint venture involving Pathos AI, indicating efforts to enhance revenue growth [1] - A joint venture with SoftBank was also announced, aimed at entering the Japanese market to drive revenue growth [1] - The acquisition of Ambry Genetics is highlighted, with claims of high revenue potential attributed to strong relationships with healthcare providers [1]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Twist Bioscience Corporation, alleging that insiders made materially false statements and failed to disclose adverse facts about the company's business and operations [1] Group 1 - The investigation is based on a federal securities lawsuit claiming that insiders at Twist Bioscience overstated the commercial viability of the company's synthetic DNA manufacturing technology [1] - The lawsuit also alleges that the company engaged in accounting fraud and used unsustainable pricing strategies to inflate its financial condition and prospects [1]

Core Viewpoint - The Dow class action lawsuit alleges that Dow Inc. and its executives made misleading statements regarding the company's financial health and ability to manage macroeconomic challenges, leading to significant investor losses during the specified class period [3][4][5]. Group 1: Class Action Details - The class action lawsuit is titled Sarti v. Dow Inc., No. 25-cv-12744 (E.D. Mich.), and it involves purchasers of Dow securities from January 30, 2025, to July 23, 2025 [1]. - Investors have until October 28, 2025, to seek appointment as lead plaintiff in the lawsuit [1][6]. - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its business and financial condition [3]. Group 2: Allegations and Financial Impact - The lawsuit alleges that on June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which was attributed to ongoing weakness in key markets [4]. - Following this downgrade, Dow's stock price fell by over 3% [4]. - On July 24, 2025, Dow reported a non-GAAP loss per share of $0.42, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [5]. - Dow's CEO attributed the disappointing results to a challenging earnings environment and announced a dividend cut from $0.70 to $0.35 per share, leading to a stock price drop of over 17% [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7][8].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. and its executives for allegedly misleading investors about the company's advertising revenue and growth potential during the specified class period from April 29, 2025, to August 5, 2025 [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Snap's executives created a false impression of reliable information regarding expected advertising revenue while downplaying macroeconomic instability [3]. - On August 5, 2025, Snap reported disappointing second-quarter results, revealing a significant deceleration in advertising revenue, which led to a stock price drop of over 17% [4]. Group 2: Legal Process and Firm Background - Investors who purchased Snap securities during the class period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of all class members [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - The Charter Communications class action lawsuit alleges that the company and its executives made misleading statements regarding the impact of the Federal Communications Commission's Affordable Connectivity Program (ACP) ending, which affected customer declines and revenue growth [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Sandoval v. Charter Communications, Inc., and it involves purchasers or acquirers of Charter Communications securities from July 26, 2024, to July 24, 2025 [1]. - Investors have until October 14, 2025, to seek appointment as lead plaintiff in the lawsuit [1][5]. - The lawsuit claims that Charter Communications failed to manage the impact of the ACP ending, leading to significant customer declines and revenue issues [3]. Group 2: Financial Impact - On July 25, 2025, Charter Communications reported second quarter 2025 financial results, showing EBITDA of $5.7 billion, indicating a growth of 0.5% [4]. - The company experienced a decline of 117,000 Internet customers, with approximately 50,000 disconnects attributed to the end of the ACP [4]. - Following the financial results announcement, Charter Communications' stock price fell by more than 18% [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder litigation [6]. - The firm has secured over $2.5 billion for investors in securities-related class action cases in 2024, ranking first in monetary relief for investors [6].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Microvast Holdings, Inc. related to misrepresentation and nondisclosure of critical information affecting shareholders [1]. Group 1: Allegations of Misconduct - Insiders at Microvast allegedly caused the company to misrepresent or fail to disclose that there was a reasonable likelihood of not being awarded the Department of Energy Grant after due diligence [2]. - It is claimed that negotiations for the Grant had ceased and the Grant was rescinded, which was not disclosed to shareholders [2]. - The company is accused of misrepresenting the nature and profitability of its businesses and partnerships, leading to materially misleading positive statements about its operations and prospects [2].